Bioinformation 18(3): 180-183 (2022)

©Biomedical Informatics (2022)





www.bioinformation.net Volume 18(3)

Received November 28, 2021; Revised March 21, 2022; Accepted March 31, 2022, Published March 31, 2022

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Edited by P Kangueane Citation: Kannayiram *et al.* Bioinformation 18(3): 180-183 (2022)

Molecular docking analysis of flavonoids with aldose reductase

Kasthuri Kannayiram¹, Vidhya Rekha Umapathy², Y. Chamundeswari³, J.H. Fathima⁴, Ramajayam Govindan⁵, Chella Perumal Palanisamy⁶, Vishnu Priya Veeraraghavan⁷, Selvaraj Jayaraman^{7,*} & Ponnulakshmi Rajagopal⁸

¹Department of Biochemistry, Tagore Medical College and Hospital, Melakottaiyur, Chennai, India; ²Department of Public HealthDentistry, Sree Balaji Dental College and Hospital, Pallikaranai, Chennai-600 100, India; ³Department of Biochemistry, Allied Health science, Dr. M.G.R Educational and Research Institute, Chennai India; ⁴Department of Oral and Maxillofacial Pathology, Ragas Dental College and Hospitals, Chennai, India; ⁵Multi Disciplinary Research Unit, Madurai Medical College, TamilNadu, India; ⁶State Key Laboratory of Bio-based Materials and Green Papermaking, College of Food Science and Engineering, Qilu University of Technology, Shandong Academy of Science, Jinan 250353, China; ⁷Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; *Corresponding author

Authors contacts:

Kasthuri Kannayiram-E-mail: kasthuridivaagar@gmail.com Vidhya Rekha Umapathy - E-mail: drvidhyarekha@gmail.com



Research Article

DOI: 10.6026/97320630018180

Bioinformation 18(3): 180-183 (2022)

Y Chamundeswari - E-mail: chamundeswariyaragorla@gmail.com JH Fathima - E-mail: shaziafathimarizwan@gmail.com Ramajayam Govindan -E-mail: endoibmsramajayam@gmail.com Chella Perumal Palanisamy - E-mail: perumalbioinfo@gmail.com Vishnu Priya Veeraraghavan - E-mail: drvishnupriayav@gmail.com Selvaraj Jayaraman - E-mail: selvarajj.sdc@saveetha.com Ponnulakshmi Rajagopal - E-mail: ragslaks@gmail.com

Abstract:

Diabetes mellitus is a group of metabolic disorders that has risen to become the third most common cause in humans in recent years. The development of new bioactive substances from natural sources is a relatively new area. Flavonoids are believed to have a variety of beneficial properties in nature, including anti-inflammatory, antimicrobial, anticancer, antioxidant, neuroprotective, and anti-HIV properties. 15 naturally occurring flavonoids docked with the selected target aldose reductase. We report the optimal binding of Acumitin, Agathisflavone, Agehoustin B, and alpha-Toxicarol with aldose reductase for further consideration in drug discovery for T2DM.

Keywords: Diabetes, molecular docking, aldose reductase, flavonoids

Background:

the global prevalence of diabetes is constantly rising, reaching approximately 382 million in 2013 and possibly reaching 591 million by 2035 [1]. Molecular docking is an effective method for discovering new small molecule drugs that target proteins [2]. Aldose reductase is a member of the super family of Aldo-keto reductases. This is the first rate-limiting enzyme in the polyol pathway, converting glucose to sorbitol with the help of NADPH as a cofactor. The enzyme sorbitol dehydrogenase catalyzes the conversion of sorbitol to fructose [3]. The polyol pathway is a relatively minor mode of glucose utilization, responsible for less than 3% of total glucose utilization. However, when blood glucose levels are elevated, this pathway becomes more active and can account for up to 30% of total glucose intake [4]. During diabetes, abnormal activation of the polyol pathway results in an increase in osmotically active sorbitol, which causes osmotic and oxidative stress, resulting in tissue damage [5]. Though, inhibiting aldose reductase is a fundamental approach to preventing and treating diabetic complications and a possible target for drug development [6]. The aim of this study is to identify potential lead drug molecules from flavonoids that inhibit aldose reductase. Flavonoids are synthesized through the phenylpropanoid pathway, which converts phenylalanine to 4-coumaroyl-CoA, which would then be transferred to the flavonoid pathway [7]. They exhibit a broad spectrum of biological activities, including antioxidant [8], anticancer [9], antibacterial [10], antifungal [11], and antiviral [12]. Therefore, it is of interest to document the Molecular docking analysis of flavonoids with aldose reductase.

Materials and Methods:

Ligand preparation:

15 Flavonoids compounds were chosen from the National NPACT natural compound database (**Table 1**). These molecules were downloaded in Structure Date File (SDF) format and converted to Protein Data Bank (PDB) coordinates by using Open Babel (http://openbabel.org) converter.

Protein preparation:

The structure of aldose reductase complexed with peptide substrate was obtained from PDB data bank (PDB Code: 1IEI). The resolution factor is 1.45Å and the method of incorporation is X-ray diffraction method. The receptors were minimized using the Swiss PDB viewer, and the active site residue was identified. The ligand molecules associated to the target have been picked using the control panel of this stand-alone program. All residues surrounding the ligand have been identified and picked. The ligand molecules were separated using Argus lab, and the final preparation was accomplished by removing water molecules and adding H –atoms.

Table 1: List of selected Flavonoids for the present study

S. No	Compound Name	
1	Acacetin	
2	Acumitin	
3	Agathisflavone	
4	Agehoustin A	
5	Agehoustin B	
6	alpha-Naphthoflavone	
7	alpha-Toxicarol	
8	Alpinone	
9	Alpinumisoflavone	
10	Amentoflavone	
11	Anemone blue anthocyanin 1	
12	Anemone blue anthocyanin 2	
13	Apigenin 7-O-neohesperidoside	
14	Apigenin	
15	Apigenin-7-O-glucoside	

Molecular docking:

The molecular docking analyses were carried using the PyRx docking method through AutoDock VINA programme to determine the potential mode of interaction between selected phytocompounds with aldose reductase protein [13, 14]. In the PyRx tool, the macromolecule was uploaded, which immediately eliminates the solvent molecules followed by measurements of hydrogen addition and gasteiger charges. In the PyRx tool associated with AutoDock VINA, the small molecules were uploaded. The receptor and compounds were translated into a pdbqt format. On the active sites of the protein, the Grid centre was located. To optimize the binding conformational analysis, the

Bioinformation 18(3): 180-183 (2022)

default exhaustively value has been used. Based on binding affinity values (kcal/mol) and bonding interaction patterns, the produced docked complexes were examined (hydrogen, hydrophobic, and electrostatic). The docked complexes were graphically described by PyMOL version 1.7.2 (PyMOL Molecular Graphics System) programme (DeLano Scientific LLC, San Carlos, CA, USA).




Figure 1: Molecular interaction of Aldose reductase with a) Acumitin b) Agathisflavone c) Agehoustin B d) alpha-Toxicarol

 Table 2: Molecular docking results obtained from PyRx

S.No	Compound Name	Docking Score kcal/mol	Hydrogen bond
1	Acumitin	-7.4	PHE-161
			GLN-192
			ARG-296
2	Agathisflavone	-7.2	ASN-182
			GLN-192
			ARG-296
3	Agehoustin B	-6.5	ARG-225
			AGR-296
4	Alpha-Toxicarol	-6.3	CYS-298
			ALA-299

Results and Discussion:

The conventional therapeutic method offers several possibilities for the treatment of several illnesses that have yet to be explored. If modern computational chemistry methods are used to investigate the ability of the conventional medicinal method, astounding results can be obtained. Numerous scientists have taken away similar experiments in the past in which bioactive compounds are docked on a specific receptor to determine its affinity. The docking poses in this study were rated according to their docking ratings. The best four compound complexes (Acumitin, Agathisflavone, Agehoustin B, and alpha-Toxicarol) were chosen based on these scoring parameters (Table 2). The docked positions of selected compounds with aldose reductase confirmed the ligand's binding positions with the enzyme. If a compound has a lower binding energy in docking experiments, this indicates that the compound could have a higher activity. The four compounds chosen had the lowest binding energies with the target protein. The hydrogen bond also plays a critical role in the inhibitory action of the target protein. All four compounds developed several hydrogen bond interactions with the target protein, indicating that they have the ability to inhibit aldose reductase activity. PHE-161, GLN-192, ARG-296, ASN-182, ARG-225, CYS-298, and ALA-299 form hydrogen bond interactions with AR in an alternate fashion (**Figure 1**).

Additionally, the Insilco findings demonstrated that lead molecules can substantially reduce intracellular sorbitol accumulation, which has been implicated in the pathogenesis of late-onset diabetic complications such as retinopathy, neuropathy, and nephropathy. The majority of synthetic Aldose reductase (AR) inhibitors have been removed from the market due to adverse side effects and suboptimal pharmacokinetic properties. Now, we're looking for a safe and efficient lead molecule to help us develop more effective AR inhibitors. Numerous reports exist in the literature describing the inhibitory action of various phytochemicals derived from historically essential medicinal plants on aldose reductase. Thus, compounds discovered via this process can also serve as a potential AR inhibitor after experimental verification.

Conclusion:

We report the optimal binding of Acumitin, Agathisflavone, Agehoustin B, and alpha-Toxicarol with aldose reductase for further consideration in drug discovery for T2DM.

Source of funding: Nil

Conflict of interests: None declared.

Reference:

- [1] Amalan V et al. Biomed Pharmacother. 2016 84:230. [PMID: 27662473]
 - [2] Wang J et al. Proteins. 1999 36:1. [PMID: 10373002]
 - [3] Kaushik P et al. Adv Bioinformatics 2014 2014:903246.[PMID: 25114678]
 - [4] Rajalakshmi M et al. Afr. J. Pharm. Pharm. 2009 3:171. https://academicjournals.org/articles/search?q=AA1 23FE34034
 - [5] Khanal CP *et al. J. of Institute of Sci. Tech.* 2013 **18**:93. https://www.nepjol.info/index.php/JIST
 - [6] Dahiya L et al. Comb Chem High Throughput Screen. 2017 20:310. [PMID: 28302016]
 - [7] Falcone Ferreyra ML *et al. Front Plant Sci.* 2012 3:222. [PMID: 23060891].
 - [8] Leong CN et al. Food Chem. 2008 109:415. [PMID: 26003366].
 - [9] Li S et al. Cancer Lett. 2010 298:222. [PMID: 20674153]
 - [10] Tagousop CN et al. BMC Complement Altern Med. 2018 18:252. [PMID: 30219066]
 - [11] Tasdemir D et al. Antimicrob Agents Chemother. 2006 50:1352. [PMID: 16569852]
 - [12] Reutrakul V et al. Planta Med. 2007 73:683. [PMID: 17562490]

ISSN 0973-2063 (online) 0973-8894 (print)

Bioinformation 18(3): 180-183 (2022)

©Biomedical Informatics (2022)

- **[13]** Trott O *et al. J Comput Chem.* 2010 **31**:455. [PMID: 19499576]
- **[14]** Morris GM *et al. J Comput Chem.* 2009 **30**:2785. [PMID: 19399780]

